We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
- Authors
Regidor, Bernard Sean; Siddiqi, Dilawer; Beatty, Bethany Marie; Goldwater, Marissa‐Skye; Jew, Scott; Bujarski, Sean; Swift, Regina; Kim, Susanna; Berenson, James R.
- Abstract
This study identifies a potential effective therapeutic approach and treatment option for RRMM patients with t(11;14) with prior exposure to anti-CD38 medications and should lead to more extensive evaluation of this combination therapy regardless of time from prior exposure to a CD38 antibody as part of another treatment regimen. Keywords: anti-CD38; daratumumab; multiple myeloma; venetoclax EN anti-CD38 daratumumab multiple myeloma venetoclax 222 223 2 01/19/23 20230201 NES 230201 NOVELTY STATEMENT What is the new aspect of your work? Regardless of the time elapsed from previous anti-CD38 monoclonal antibody (mAb) exposure in another regimen, retreatment with anti-CD38 mAb therapy combined with venetoclax is effective for relapsed/refractory multiple myeloma (RRMM) patients with t(11;14).
- Subjects
MULTIPLE myeloma; VENETOCLAX; MEDICAL personnel; IMMUNOGLOBULINS; DARATUMUMAB
- Publication
European Journal of Haematology, 2023, Vol 110, Issue 2, p222
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13896